CRISPR has arrived into the gene therapy field as its own entity. It is a powerful and accurate gene editing tool that can make acute changes and repairs to damaged DNA. In the three years corporations have been operating in the space, three major IPOs have occurred totaling at more than $200 million in capital raised. As new CRISPR products are still making their way through clinical trials, now is an ideal time to lodge holdings in the industry.